Board summary
Key figures
71,977
Registered population
69.7% aged 18–64
15.3%
Aged 65+
ICB 21.9% · England 17.9%
16.1%
Ethnic minority (non-White)
5.5% Asian · England 9.6%
41.3%
In IMD quintile 1
ICB 9.2% · England 21.0%
~26,484
Core20 residents (est.)
Resident basis; registered basis ~31,703 · see page 3
8,996
Hypertension register
+3.42% in 3 yrs · England +5.60%
1,444
SMI register
31.2% of Brighton and Hove (LAD)'s
1,813
COPD register
Reviews +2.94% in 3 yrs
Forecast to 2030
9,635
Hypertension patients, 2030
+639 on today
67.8%
QRISK ≥20% on statins, 2030
+4.00pp over 3 yrs
3.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail England (65.7%).
Across 5,331 asthma patients (7.4% prevalence), 59.4% had an annual review (England 65.7%), leaving about 2,200 unreviewed; three-year change was +0.1% (England +4.4%).
SMI physical health checks lag behind England.
Psychosis alcohol recording is 64.0% (England 81.8%, down 1.4 pp vs England +5.4 pp) and SMI blood pressure checks reach 74.8% (England 83.4%).
Lipid therapy and SMI BMI trends beat England.
Three-year growth in lipid-lowering therapy for QRISK ≥ 20% (+7.3% vs England +6.2%) and SMI BMI recording (+6.1 pp vs +5.1 pp) exceeded England.
Population, age and ethnicity
Working-age adults comprise 69.7% of registered patients alongside 11,044 older adults
Of 71,977 registered patients, 69.7% are aged 18–64 (Brighton and Hove 71.4%, NHS Sussex ICB 60.5%, England 62.7%) and 15.3% are aged 65+ (11,044 patients; Brighton and Hove 14.0%, NHS Sussex ICB 21.9%, England 17.9%). Census usual-resident data records 83.9% White (Brighton and Hove 85.4%, NHS Sussex ICB 91.0%, England 81.1%) and 16.1% non-White ethnic groups, with Arch Healthcare's catchment reaching 15.6% Asian and 7.6% Black residents. Projected growth to 2030 is 0.3% under unverified ONS modelling (Brighton and Hove 0.7%, NHS Sussex ICB 2.1%, England 2.3%). Catchment areas include 15 care homes with 503 beds.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Brighton and Hove (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Brighton and Hove LA) | 2,702 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 75.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 52.6% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Brighton and Hove LA) | 1,485 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Brighton and Hove LA) | 19.9 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients comprise 41.3% of the PCN, spanning 87.3 pp across member practices
Core20 patients comprise 41.3% of registered patients, exceeding England (21.0%), Brighton and Hove (17.6%) and NHS Sussex ICB (9.2%). Across practices, shares span 87.3 pp, from 12.7% at Woodingdean Medical Centre to 100.0% at Arch Healthcare. The PCN rate (41.3%) and practice-weighted share (44.0%) differ by 2.75 pp. St. Peter's Medical Centre holds the largest Core20 volume with 8,247 estimated patients (45.4%). The board must balance specialised inclusion pathways at high-concentration practices with broad clinical outreach across large-volume lists.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,444
SMI register
1.93% recorded prevalence
511
Learning disability register
0.68% recorded prevalence
15
Care homes, 503 beds
In the PCN catchment
8.2%
Provide unpaid care
Brighton and Hove (LAD), Census 2021
The PCN records 1,444 severe mental illness patients (1.9% vs Brighton and Hove 1.4%, NHS Sussex ICB 1.1%, England 1.0%), representing 31.2% of the borough register, and 511 learning disability patients (0.7% vs 0.6% across comparators). The SMI register is above the England rate, so physical-health checks for this group are the larger workload to protect.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.9% (England 1.0%), yet annual blood pressure checks reach 74.8% (England 83.4%) and psychosis alcohol recording is 64.0% (England 81.8%). Prioritising physical health recall across these 1,444 patients could close monitoring gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,996
Hypertension register
+3.42%
Register growth, 3 yrs
Brighton and Hove (LAD) +7.27% · England +5.60%
+1.45pp
BP control, under 80
≤140/90 · −0.42pp aged 80+
+639
More patients by 2030
Forecast 9,635 (12.84%)
Hypertension case-finding and control
Hypertension prevalence is 12.0% (8,996 patients), above Brighton and Hove (10.5%) but below England (15.2%) and NHS Sussex ICB (16.3%), with unconfirmed matching observation bases. While 87.9% of hypertensive patients had a recent blood pressure reading (England 90.0%), treatment to target reaches 64.7%, trailing England (70.3%), Brighton and Hove (66.5%) and the ICB (69.1%). For patients aged under 80, control is 63.7% (England 67.8%), and for those aged 80 and over it is 77.0% (England 81.2%). Blood pressure control lags national benchmarks across age groups despite high monitoring rates, suggesting the PCN could prioritise systematic medication reviews and titration protocols.
Lipids and statins
Lipid therapy reaches 58.9% of patients with QRISK ≥ 20%, matching Brighton and Hove (58.9%) but trailing NHS Sussex ICB (60.0%) and England (63.6%), despite +7.3% three-year change (England +6.2%). Fewer at-risk patients are on lipid-lowering therapy than the England rate would imply, so a recall audit could be considered.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 114,780 | £2.20 | £2.42 | £1.86 | £252,516 |
| Cardiovascular (all), 2025 | 147,985 | £2.61 | £3.32 | £3.33 | £386,241 |
For lipid-regulating drugs in 2026, the PCN prescribed 114,780 items at £2.20 per item (Brighton and Hove £2.47, NHS Sussex ICB £2.42, England £1.86), spending £39,025 more than at England's unit cost. Higher unit costs than England for lipid-regulating drugs could reflect local formulary choices, which could be examined through clinical audit.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+0.13%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.98%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.4% (England 6.6%), covering 5,331 registered patients, alongside youth prescribing of 1,807 items per 1,000 aged 5-19 (England 1,488 rate). Annual reviews reach 59.4% (England 65.7%), leaving about 2,200 patients unreviewed, while second-hand smoke recording reaches 70.8% (England 78.8%). COPD prevalence is 2.4% (England 1.9%, 1,813 patients), with reviews at 70.2% (England 76.4%). Lagging review completion alongside elevated prescribing suggests routine review capacity may not be keeping pace with respiratory disease burden.
Cancer register and children's immunisation
Cancer prevalence is 3.1% (2,325 patients), below England (3.8%). In childhood immunisations, 6-in-1 coverage at 12 months reaches 92.2% (target 95.0%). By age 5, first-dose MMR reaches 94.6%, but second-dose MMR falls to 89.2% (a 5.4 pp drop) and the 4-in-1 booster reaches 85.8%, lagging the 95.0% standard by 9.2 pp. Pre-school booster attrition leaves older children under-protected, indicating a need for targeted recall before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
For NHS Sussex ICB in 2022, 58.5% of staged cancers across all cancer sites were diagnosed at stage 1 or 2 (4,799 of 8,209 known-stage cases), above England (55.3%) by 3.2 percentage points but 16.5 pp below the 75.0% national ambition. Known-stage cancers formed 64.3% of registered diagnoses (8,209 of 12,766). Reaching the 75.0% ambition across the ICB would require about 1,360 additional early-stage diagnoses. System staging does not reflect PCN performance, but East & Central Brighton PCN lags on screening: cervical screening coverage at ages 25-49 is 57.6% (England 66.8%) and breast screening at ages 53-70 is 62.0% (England 69.9%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At University Hospitals Sussex NHS Foundation Trust, the 62-day referral to treatment standard trailed the 85.0% operational standard by 19.8 pp, while the 31-day combined treatment standard trailed the 96.0% standard by 19.2 pp, and the 28-day faster diagnosis standard was 1.0 pp below the 75.0% standard. Across NHS Surrey and Sussex Integrated Care Board, performance was 13.5 pp below the 85.0% 62-day standard and 5.6 pp below the 96.0% 31-day standard, but 4.3 pp above the 75.0% faster diagnosis standard. These secondary-care waits could reflect acute pathway bottlenecks that may prolong diagnostic and treatment intervals, unverified locally.
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 27.53 | 21.40 |
| CT | 8.57 | 0.48 | 18.49 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 43.78 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 15.11 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 21.06 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 28.50 | 23.14 |
| Community services activity | Brighton and Hove residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 23,615 | 309,615 |
| Referrals | 5,590 | 66,930 |
| Patients with a contact | 7,350 | 85,660 |
Community services (residents of Brighton and Hove), Jun 2026 (provisional). In June 2026 (provisional), adults aged 65 and over accounted for 60.7% of all community service contacts for Brighton and Hove residents (14,325 of 23,615 contacts). This reflects local authority resident activity rather than PCN-specific delivery, indicating high community service use among older borough residents that interfaces with primary care chronic disease pathways.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Arch Healthcare | 88 | 100.0 | 92.5% | 78.6% | 100.0% |
| Ardingly Court | 132 | 50.2 | 73.1% | 77.7% | 91.7% |
| Pavilion Surgery | 132 | 49.7 | 85.0% | 78.4% | 90.6% |
| Broadway Surgery | 97 | 69.2 | 69.1% | 68.4% | 85.3% |
| Wellsbourne | 109 | 59.8 | 59.9% | 72.6% | 83.1% |
| Regency Surgery | 93 | 59.7 | 79.4% | 72.4% | 80.4% |
| St. Peter's | 96 | 45.4 | 38.5% | 58.8% | 74.9% |
| Woodingdean | 111 | 12.7 | 36.4% | 65.5% | 71.7% |
| Park Crescent | 110 | 27.2 | 33.8% | 58.2% | 60.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nineteen of 25 tracked measures trail England's three-year trend, led by dementia registers
Across 25 tracked indicators, 19 trail England's three-year trend. The widest relative lags are falling registers for dementia, which fell 6.1% (England +6.0%, a 12.16-point lag), and learning disability, which fell 3.8% (England +5.4%, a 9.21-point lag). In care processes, psychosis alcohol recording fell 1.4 pp (England +5.4 pp). Conversely, relative gains occurred in QRISK ≥ 20% lipid therapy, rising +7.3% (England +6.2%), and severe mental illness BMI checks, rising +6.1 pp (England +5.1 pp). These trailing trajectories could reflect coding variations or list turnover, which remain unverified locally.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Learning disability register
Alcohol record (psychosis)
Breast screening (53-70)
Diabetes HbA1c control
QRISK statin treatment
BMI record (SMI)
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Brighton and Hove (LAD) | Asset | PCN | Brighton and Hove (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 15 (503 beds) | n/a | Schools (catchment) | 70 | n/a |
| Children's centres | 6 | 14 | Places of worship | 49 | 113 |
| Libraries | 5 | 13 | Homelessness support (VCS) | 0 | no data |
| Primary schools (LA maintained) | 12 | 35 | Primary academies | 4 | 7 |
| Special schools | 2 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma annual reviews reach 59.4% vs 65.7% in England (6.3 pp below; Brighton and Hove 60.1%, ICB 62.5%) across 5,331 registered patients, leaving 2,165 (about 2,200) unreviewed. For discussion, the PCN could introduce a single recall template, flexible review slots, and combined inhaler-prescribing reviews. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
SMI physical health check outreach
Across 1,444 SMI patients (1.9% prevalence; 31.2% of borough register), BP checks reach 74.8% vs 83.4% in England (8.6 pp below) and alcohol recording is 64.0% vs 81.8% (17.8 pp below). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Pharmacist-led CVD and diabetes titration
Across 8,996 hypertension patients (12.0% prevalence), treatment to target is 64.7% vs 70.3% in England (5.6 pp below), QRISK >= 20% lipid therapy is 58.9% vs 63.6%, and non-frail diabetes HbA1c <= 58 mmol/mol is 52.6% vs 57.4%. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Catchment care home alignment (p2) | Count of Care Homes in PCN catchment | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026 | PCN |
| Two-track Core20 outreach model (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control protocol review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake campaign (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · SMI physical health check outreach (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Option 3 · Pharmacist-led CVD and diabetes titration (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
